Theresa LaVallee, Ph.D.

Dr. Theresa LaVallee joined Coherus in 2021 and is currently Chief Development Officer. Theresa brings more than 25 years of drug discovery and development experience in oncology and inflammation.

Prior to Coherus, Dr. LaVallee was Vice President, Translational Medicine and Regulatory Affairs at the Parker Institute for Cancer Immunotherapy where she led scientific and clinical-regulatory strategy for the development of novel immuno-oncology therapies and helped establish the institute’s clinical, translational and regulatory organization. Previously, she held executive roles at Celldex Therapeutics and Kolltan Pharmaceuticals (acquired by Celldex) where she led research, product development and regulatory strategy as well as directed translational research efforts supporting advancement of novel antibody programs in oncology. Prior to Kolltan, she worked for five years as a Senior Director and on the Oncology iMED working across oncology including on the immuno-oncology portfolio at AstraZeneca (MedImmune) developing checkpoint inhibitors and related diagnostics. Previously, she held multiple research positions over ten years at EntreMed, including Senior Director, Cell Biology.

In 2021 Dr. LaVallee was highlighted by IO360 in the Woman Leadership in Immuno-oncology Newsletter and was named in The Top 25 Woman Leaders in Biotechnology in 2023. She earned her Ph.D. from the University of California, Los Angeles and a B.A. from the University of California, Santa Barbara.